JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Interferon α (IFNα) is used to treat JAK2(V617F)-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by arsenic trioxide (ATO) drives eradication of acute...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Med
Main Authors: Dagher, Tracy, Maslah, Nabih, Edmond, Valérie, Cassinat, Bruno, Vainchenker, William, Giraudier, Stéphane, Pasquier, Florence, Verger, Emmanuelle, Niwa-Kawakita, Michiko, Lallemand-Breitenbach, Valérie, Plo, Isabelle, Kiladjian, Jean-Jacques, Villeval, Jean-Luc, de Thé, Hugues
Formato: Artigo
Idioma:Inglês
Publicado em: Rockefeller University Press 2020
Assuntos:
Brief Definitive Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7579737/
https://ncbi.nlm.nih.gov/pubmed/33075130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20201268
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados